Molecular Partners AG (MOLN) stock
MOLNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 20-F on Mar 12, 2026Score 1/30
$2.67−0.19 (-6.82%)
Close on Nov 18, 2026Market cap $107.60MP/E –Yield –
Molecular Partners revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
For fiscal 2025 it was CHF 0, down 100.0% from the year before. The highest annual figure on record is CHF 189.60M in fiscal 2022.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | CHF 0 | -100.0% |
| FY2024 | Dec 31, 2024 | CHF 4.97M | -29.4% |
| FY2023 | Dec 31, 2023 | CHF 7.04M | -96.3% |
| FY2022 | Dec 31, 2022 | CHF 189.60M | +1843.8% |
| FY2021 | Dec 31, 2021 | CHF 9.75M | +4.4% |
| FY2020 | Dec 31, 2020 | CHF 9.34M | -54.2% |
| FY2019 | Dec 31, 2019 | CHF 20.38M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | CHF 0 | -100.0% |
| Q2 FY2025 | Jun 30, 2025 | CHF 0 | – |
| Q2 FY2024 | Jun 30, 2024 | CHF 1.55M | – |
| Q2 FY2023 | Jun 30, 2023 | CHF 415.00K | – |
| Q2 FY2022 | Jun 30, 2022 | CHF 11.76M | – |
See a number that looks wrong?